Otomagnetics reduces cisplatin-related hearing loss in mice, new study shows
The Hearing Review Sep 27, 2017
Otomagnetics - a company that is developing a non-invasive method of drug delivery to the inner and middle ear, skin, and eyes - has made a breakthrough towards preventing hearing loss caused by a widely-used chemotherapy drug.
Using a new technique to deliver steroids to the inner ear, developed with funding from Action on Hearing Loss, Otomagnetics has been able to reduce hearing loss in mice treated with the chemotherapy drug cisplatin by 50%, according to the announcement.
Steroids can reduce cisplatin-induced hearing loss but they may also reduce the effectiveness of cisplatinÂs ability to kill cancer cells. This means they need to be directly delivered to the cochlea to be effective and to avoid this side effect. The current approach is to inject liquid steroids through the ear drum into the middle ear from where they can diffuse into the cochlea. However, this method is not very efficient as the steroid is lost via the Eustachian tube as soon as the patient stands up, so doesnÂt get into the cochlea at high enough concentrations to prevent hearing loss.
OtomagneticÂs new approach to getting drugs into the cochlea uses magnetic fields to push drug-covered iron nanoparticles into the cochlea. The approach is reportedly more efficient than a normal intra-tympanic injection. The technique could be used to deliver any drug to the ear and can also be used to deliver drugs into eyes or into the skin.
Dr Ralph Holme, director of research at Action on Hearing Loss said, ÂIt is vital that we find effective ways of getting drugs into the inner ear, which is why we are backing Otomagnetics. It is great news that progress is being made towards finding new ways to protect childrenÂs hearing following cancer treatment with cisplatin which causes the sensory hair cells in the cochlea that detect sound to die and can leave cancer survivors who have already gone through a traumatic experience, depressed and isolated.Â
Otomagnetics anticipate that their magnetic delivery method could also be used to deliver a wide range of drug, gene, and stem cell-based treatments to ultimately treat many different types of hearing loss.
The findings were published in the journal Frontiers in Cellular Neuroscience on September 13.
Go to Original
Using a new technique to deliver steroids to the inner ear, developed with funding from Action on Hearing Loss, Otomagnetics has been able to reduce hearing loss in mice treated with the chemotherapy drug cisplatin by 50%, according to the announcement.
Steroids can reduce cisplatin-induced hearing loss but they may also reduce the effectiveness of cisplatinÂs ability to kill cancer cells. This means they need to be directly delivered to the cochlea to be effective and to avoid this side effect. The current approach is to inject liquid steroids through the ear drum into the middle ear from where they can diffuse into the cochlea. However, this method is not very efficient as the steroid is lost via the Eustachian tube as soon as the patient stands up, so doesnÂt get into the cochlea at high enough concentrations to prevent hearing loss.
OtomagneticÂs new approach to getting drugs into the cochlea uses magnetic fields to push drug-covered iron nanoparticles into the cochlea. The approach is reportedly more efficient than a normal intra-tympanic injection. The technique could be used to deliver any drug to the ear and can also be used to deliver drugs into eyes or into the skin.
Dr Ralph Holme, director of research at Action on Hearing Loss said, ÂIt is vital that we find effective ways of getting drugs into the inner ear, which is why we are backing Otomagnetics. It is great news that progress is being made towards finding new ways to protect childrenÂs hearing following cancer treatment with cisplatin which causes the sensory hair cells in the cochlea that detect sound to die and can leave cancer survivors who have already gone through a traumatic experience, depressed and isolated.Â
Otomagnetics anticipate that their magnetic delivery method could also be used to deliver a wide range of drug, gene, and stem cell-based treatments to ultimately treat many different types of hearing loss.
The findings were published in the journal Frontiers in Cellular Neuroscience on September 13.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
